Phase 4
Completed N=106
Efficacy of Losartan in Preventing Progression of COPD
Source: ClinicalTrials.gov NCT00720226 ↗Enrolled (actual)
106
Serious AEs
23.6%
Results posted
Apr 2017
Primary outcomePrimary: Change in Percent Emphysema on CT Scan — -0.32; 2.18 % Emphysema Whole Lung — p=0.06
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
Evidence in animals shows that losartan can prevent or reverse inflammation and lung damage due to smoking. The goal of this study is to determine whether this drug which is also used to treat hypertension can stabilize or improve lung function in people who have from chronic obstructive pulmonary disease (COPD).
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Percent Emphysema on CT Scan |
-0.32; 2.18 | 0.06 |
| SECONDARY Change in FEV1 (L) |
-0.0879; -0.0581 | 0.55 |
Eligibility Criteria
Inclusion Criteria
- Adults with COPD who are either active or former smokers
Exclusion Criteria
- Clinical requirement or history of intolerance of angiotensin receptor blockers, serious heart, liver, kidney, neurological disease.
Data sourced from ClinicalTrials.gov (NCT00720226). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.